RALEIGH, N.C., Nov. 20, 2013 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it has won the 2013 U.S. Clinical Researcher of the Year's "Clinical Company of the Year" award for the second consecutive year, as well as several individual honors at the competition's finals ceremony held recently in Cary, NC. Included in PRA's individual winners was a clean sweep of the Project Management category, where PRA claimed first, second, and third place.
Organized by PharmaTimes, the event named PRA "Clinical Company of the Year" based on the total points earned by its employees' performances in individual competitions. Fourteen PRA employees across four categories were invited to attend the in-person finals competition. They competed with nearly 200 other contestants in a rigorous three-phase process that tested their skills in risk-based monitoring and virtual teamwork.
"This contest allows our employees to compete against other talented professionals in the clinical research industry," said PRA Executive Vice President of Product Registration-Americas, Andrew Strayer. "Being named 'Clinical Company of the Year' for the second year in a row is an achievement that speaks to the level of commitment and dedication of our employees."
PRA employees earning this year's awards include: Lee Steen, second place, New Clinical Research Associate category; Promise Lawrence, first place, Project Manager category; Sarah Connell, second place, Project Manager category; and Adrienne Stoudenmire, third place, Project Manager category.
One of the world's largest CROs, PRA is transforming clinical trials through our people, innovation and operational transparency. Our 10,000+ employees operate in more than 80 countries, delivering a broad spectrum of full-service and Embedded clinical trial solutions that meet the demands of a diverse marketplace.
PRA's Early Development Services group is committed to the highest standards of clinical excellence and scientific expertise. We operate state-of-the-art facilities in The Netherlands and North America as well as an innovative patient pharmacology model in Central and Eastern Europe providing the pharmaceutical and biotech industries with the unique scientific environment required for complex compound development and testing. In addition, PRA's harmonized laboratory facilities in The Netherlands and the US are situated close to the clinical facilities and are configured to fully support all clinical study requirements.
Over the last 30+ years, PRA has established a reputation for specialized expertise and success in a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. Our forward-thinking approach to clinical research innovation, customized recruitment strategies and technological advances continues to make a difference to healthcare patients around the world.
To learn more about PRA, please visit praintl.com, email firstname.lastname@example.org.